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Vitamin E is an important natural antioxidant, and its most common and biologically active form is α-tocopherol. In
addition to this, specific regulatory effects of vitamin E have been revealing. The body exerts a certain effort to regulate
its tissue levels with specific tocopherol transport proteins and membrane receptors. Antiproliferative and protein kinase
C-supressing effects of alpha-tocopherol have been previously demonstrated, which have not been mimicked by beta-
tocopherol or probucol. Protein kinase C promises to be an important area of interest in the means of glaucoma and
cataractogenesis. It has been shown in different models that retinal vasculer dysfunction due to hyperglycemia could be
prevented by alpha-tocopherol via the diachylglycerol-protein kinase C pathway. Glutamate transporter activity has been
shown to be modulated by protein kinase C. This pathway is also important in intraocular pressure-lowering effects of
prostaglandin and its analogs in glaucoma therapy. Filtran surgery became another possible area of usage of alpha-
tocopherol since its antiproliferative effect has been demonstrated in human Tenon's capsule fibroblasts. Prevention of
posterior capsule opacification is another area for future studies. It is evident that when correct and safe modulation is the
objective, alpha-tocopherol merits a concern beyond its mere antioxidant properties.
Vitamin E is a natural, highly tolerable and cost effective
molecule.  This  generic  term  is  used  for  tocopherol  and
tocotrienols consisting of two rings with a hydrocarbon chain.
Both structures are similar, although the tocotrienol structure
has double bonds on the isoprenoid units. Natural vitamin Es
are known as α, β, γ, and δ according to the methyl or proton
groups that are bound to their Benzene rings, and the most
common  and  biologically  active  form  is  alpha-tocopherol
(Figure 1) [1]. When produced synthetically, it is composed
of eight stereoisomers in which RRR-α-tocopherol is the most
biologically active form [2].
While  the  recommended  daily  allowance  (RDA)  for
vitamin E is 8 mg (12 IU) for females and 10 mg (15 IU) for
males, Packer [3] recommends up to 1,000–1,200 IU intake
of  vitamin  E  in  some  pathologies  including  cataract.  The
principal reserve of natural vitamin E is vegetable oil where
its function is to protect tissue from oxidative demage. It is a
liposoluble  molecule,  and,  therefore,  after  dietary  intake,
vitamin E is not only absorbed easily from the intestinal lumen
but  is  also  dispersed  between  lipids  and  proteins  in  cell
membranes. Vitamin E molecules can interrupt free radical
chain reactions by capturing the free radical. This imparts to
them their antioxidant properties. The free hydroxyl group on
the aromatic ring is responsible for the antioxidant properties.
The hydrogen from this group is donated to the free radical,
resulting in a relatively stable free radical form of vitamin E
(Figure 2) [2].
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Regarding the pharmacodynamics of tocopherols, it has
been reported in a study conducted in human eyes that the
retinal levels of vitamin E are higher than those of the choroid
or vitreous and is correlated with serum levels of vitamin E
[4]. It is known that vitamin E can only reach its theraupetic
levels in aqueous humor and lens via topical application and
is accumulated within the retina when applied via the oral or
parenteral route [5]. Moreover, it is reported in animal studies
that  when  100  mg/kg  α-tocopherol  is  applied  via  oral  or
parenteral  route,  it  causes  a  similar  threefold  to  sixfold
increase to its serum levels, though the retinal and vitreal
increases are somewhat slower via the oral route [6].
Based on the common knowledge summarized above,
vitamin E is occasionally prescribed in ophthalmology clinics.
This article provides an overview of the existing literature
regarding other effects of this molecule that illuminates the
potential  usage  of  this  drug  as  an  effective,  specific
therapeutic tool in several ocular pathologies.
DISCUSSION
Beyond the nonspecific antioxidant effect: Specific effects of
Vitamin  E,  which  includes  gene  regulation,  have  been
revealing, and non-antioxidant properties of tocopherols are
current topics of interest [7]. In many in vivo and in vitro
studies, the antiproliferative effect vitamin E has been shown
[8-10].
Protein kinase C (PKC) is one of the pathways used by
α-tocopherol [11]. Sharma et al. [12] reported that tocopherol
inhibits not only free radical formation but also tyrosine kinase
activity  in  Tissue  Plasminogen  Activator  (TPA)-induced
primary human fibroblasts or HL-60 cells. Results of many
published in vivo and in vitro collaborative studies illuminate
the  antiproliferative  effect  of  α-tocopherol  via  the  PKC
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855pathway in the vascular smooth muscle cell model, and they
have been summarized by Ozer et al. [13]. In smooth muscle
cell  cultures,  neither  the  antiproliferative  nor  the  PKC-
supressing effects of α-tocopherol have been shown by its
isomer, β-tocopherol, or another antioxidant, probucol. It is
also shown that, 3H Timidin incorporations and PKC activities
gradually decline as the α-tocopherol level in the medium
rises. On the other hand, linkage of Activator Protein (AP-1)
to DNA has been supressed by the application of α-tocopherol
in  para-methoxyamphetamine  (PMA)-stimulated  cells,  but
this effect has not seen in phase G0 cells. These findings are
also  succesfully  supported  by  rabbit  studies  in  the
atherosclerosis model.
The existence of sensitive mechanisms to regulate tissue
levels is an important and distinctive feature of vitamin E
[10,14]. The tocopherol transfer protein, responsible for the
intracellular transportation of vitamin E, has been shown and
described in cell cultures [15], animals [16-19], and various
human  tissues  [20-22].  Furthermore,  discovery  of  α-
tocopherol specific membrane receptors [23] and cytosolic
transfer proteins strengthen the thesis that vitamin E possesses
properties  beyond  a  mere  antioxidant  function  [10].
Specifically for the eye, scavenger receptor class B type I at
the inner blood-retinal barrier has been described in vitro,
which  is  responsible  for  α-tocopherol  uptake  from  the
circulating  blood  and  plays  a  key  role  in  maintaining  α-
tocopherol in the neural retina [24].
Clinical importance: Protective effects of vitamin E have
been shown in almost all eye tissues with in clinical, in vitro,
and in vivo studies. For instance, vitamin E is known to double
the  rabbit  corneal  endothelial  cell  survival  time  [25]  and
enhances retinal cell survival via its effect on mitochondrial
activity [26]. Also, α-tocopherol can protect the retina from
light injury for up to 24 h of exposure [27]. Vitamin E plays
an important prophylactic role against several serious light-
induced diseases and conditions of the eye (cataractogenesis
and  retinal  photodeterioration)  and  skin  (erythrocyte
photohemolysis,  photoerythema,  photoaging,  and
photocarcinogenesis)  that  are  mediated  by  photooxidative
damage to cell membranes [28]. These findings do not have
to be explained with antioxidant mechanisms, especially for
α-tocopherol. As Azzi [20] stated: “A number of lines of
Figure 1. Molecular structure of α-tocopherol. Shown is the molecular structure of α-tocopherol, consisting of two benzene rings with a
hydrocarbon chain
Figure 2. Antioxidant mechanism of tocopherols. LH: Lipid molecule, LOOH: Lipid peroxide, LOO+: Lipid Peroxide radical, a-Toc-OH: α-
Tocopherol, a-Toc-O+: α-Tocopherol radical, GSH: Glutathione, Vitamin C+: Vitamin C radical, GS+: Glutathione radical, GSSG: Oxidized
glutathione,  NADPH:  Reduced  nicotinamide  adenine  dinucleotide  phosphate,  NADP+:  Oxidized  nicotinamide  adenine  dinucleotide
phosphate.
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856evidence, evolutionary, genetic, biochemical, and functional,
have indicated that the natural function of α-tocopherol is that
of cell signaling. Such a property is not shared by any other
antioxidant molecule.”.
An association between α-tocopherol and some ocular
pathologies  has  also  been  demonstrated  previously.  For
example, retinitis pigmentosa is shown to be related to an
H101Q mutation in the α-tocopherol transfer protein gene
[29].  The  combination  of  cryotherapy  with  vitamin  E
prophylaxis appeared to decrease the severity and sequelae of
threshold retinopathy of prematurity [30]. Average levels of
α-tocopherol were shown to be lower in people with exudative
macular degeneration [31].
Developments in the understanding of these molecules
have increased the attention paid to properties beyond their
antioxidant  function,  including  antiproliferative  effects.
Retinal  pigment  epithelium  cells  migrating  through  the
damaged retina play an important role in the pathogenesis of
proliferative vitreoretinopathy. Majon et al. [32] found that
α-tocopherol inhibits proliferation of human retina pigment
epithelium (RPE) cells in culture without exerting cytotoxic
effects. Maximal inhibition was achieved with 100 μM α-
tocopherol.  It  has  been  found  that  α-tocopherol  succinate
inhibits  proliferation  and  migration  of  retinal  pigment
epithelial cells in vitro [33]. α-Tocopherol and α-tocopheryl
acid succinate in saline solution presented a retardation of
proliferative vitreoretinopathy in retinal detachments [34].
The  protective  function  of  α-tocopherol  against  the
process  of  cataractogenesis  in  humans  is  reported  in
epidemiologic studies [35]. In the Beaver Dam Eye Study, it
is shown that age-related lens opacities in humans are linked
inversely to vitamin E status [36].
Glaucoma is another possible area of usage for vitamin
E. Failure in glaucoma surgery is primarily due to fibrocellular
scar formation, derived from Tenon's capsule fibroblasts. It
has been found that d-α-tocopherol (vitamin E) was able to
inhibit  proliferation  of  in  vitro  human  Tenon's  capsule
fibroblasts  [37].  Following  this,  filtran  surgery  became
another model in which an antiproliferative effect has been
shown  in  vivo.  α-Tocopherol  derivatives  showed
antiproliferative  properties  in  the  experimental  models  of
filtering surgery and showed better intraocular pressure (IOP)
control and bleb survival [38,39]. Cell culture studies further
illuminated this effect, and comparative studies with other
antimetabolites have been performed [40].
On the other hand, dual effects of α-tocopherol and PKC
on the eye are of interest in the means of glaucoma therapy.
Kunisaki et al. in 1995 [41] and Lee at al. in 1999 [42] showed
in different models that retinal vasculer dysfunction due to
hyperglycemia  could  be  prevented  by  α-tocopherol  via  a
diachylglycerol-PKC pathway. In a study performed by Engin
et  al.  [43],  60  glaucomatous  eyes  from  30  patients  were
divided into three groups. While group A patients recieved no
tocopherol, group B and group C patients were given 300 and
600 mg/day of oral α-tocopheril acetate, respectively. Visual
fields and retinal blood flows of ophthalmic and posterior
ciliary arteries with Doppler ultrasonography were evaluated
in the beginning of the study, as well 6 and 12 months after
treatment. Compared with group A, differences of pulsatilty
and resistivity indexes of ophthalmic and posterior ciliary
arteries were lower in groups B and C 6 and 12 months after
treatment. Posterior ciliary artery differences of resistivity
indexes in the 6th and 12th months and ophthalmic artery
differences of pulsatilty indexes reductions in the sixth month
were statistically significant. Differences of mean deviations
with visual fields in groups B and C were significantly lower
than that of group A.
Focus on protein kinase C: Among other signaling pathways
that have been shown to be affected by α-tocopherol, PKC
promises to be an important area of interest. It is a widespread
serin/threonine  kinase  responsible  for  transduction  of  the
signals taken from the G protein coupled, tyrosine kinase
receptors, and nonreceptor tyrosine kinases to the nucleus via
phospholipid  hydrolysis  [44].  c-Jun,  c-fos,  and  c-myc  are
reported to be the transcription factors that have been activated
[45].  Although  AP-1  is  the  mostly  considered  family
[46-48],  nuclear  factor  kappa-light-chain-enhancer  of
activated B cells (NF-κB) [49] and Transcriptional enhance
factor-1 (TEF-1) [50] are among other transcription factors
known to be affected by PKC.
Beside its role in retinal vasoregulation mentioned above,
the PKC pathway boasts a decisive factor in the pathogenesis
for and on the clinical course of glaucoma. Glaucoma is one
of  the  neurodegenerative  conditions  arising  from  a
compromised glutamate homeostasis. Glutamate transporter
activity has been shown to be modulated by PKC [51]. PKC
have been shown to affect nonvascular smooth muscle cells
such as the iris sphincter [52]. Wiederholt et al. [53] have
reported that various pathways and ion channels affect PKC
isomers  producing  different  responses  in  eye  nonvascular
smooth muscle cells, but in general, PKC inhibitors relax
trabecular  meshwork  while  leaving  the  ciliary  muscle
comparatively unaffected.
Alexander and Acott [54] have reported that the PKC
pathway is crucial in glaucoma therapy for the intraocular
pressure-lowering effects of Prostaglandin F 2α (PGF2α) and
its analog, latanoprost. The cytokine, Tumor Necrosis Factor
α  (TNFα),  is  a  strong  modulator  of  trabecular  meshwork
matrix metalloproteinase (MMP) and tissue inhibitor (TIMP)
expressions. TNFα treatment triggered some PKC isoform
translocations. Exposure of trabecular cells to TNFα for 72 h
differentially  downregulated  several  PKC  isoforms.
Treatment with a phorbol mitogen that stimulates most PKC
isoforms produced strong increases in these MMPs. Effects
of TNFα on MMP and TIMP expressions were completely
blocked by only one PKC inhibitor.
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857Further  studies  were  conducted  to  identify  signal-
transduction  pathways  involved.  In  a  study  performed
concerning cat iris sphincter smooth muscle cells, the relaxing
effects  of  PGF2α  and  carbachol  have  been  shown  to  be
produced by mitogen activated protein (MAP) kinases in a
PKC-dependent  manner  [55].  On  the  other  hand,  PKC
activators strongly stimulate the phosphorylation of AQP4
(aquaporin in the ciliary body) and inhibit AQP4 activity in a
dose-dependent manner [56].
The prevention of posterior capsule opacification (PCO)
is another area for future studies. Despite recent advances in
cataract  extraction,  lens  epithelial  cells  remaining  in  the
capsule proliferate and eventually cause opacification within
days of surgery [57]. Although inhibition of lens epithelial
cells can be observed with various agents, toxic side effects
to the ciliary body, cornea epithelium, and iris limit their use
in human subjects [58-60]. PCO is a process mainly involving
proliferation and migration of the lens epithelium [61], and
PKC is a signaling pathway that is known to result in major
effects on this process.
PKC activity exists in the cytosol and particulate fractions
of bovine lens epithelial cells [62], and its role in both cell
differentiation [63] and proliferation [64] have been shown in
rabbit lens epithelial cells. Furthermore, it is shown in lens
epithelial  cells  that,  12(S)HETE-dependent  activation  of
PKCα and βII acts in concert with other epidermal growth
factor (EGF)-dependent signals to induce c-fos mRNA and
that this is independent of the extracellular signal-regulated
kinases  1/2  (Erk1/2)  pathway  [65].  The  PKC  dependent
inositol signaling system also regulates K+ fluxes in these
highly proliferative lens epithelial cells primarily by affecting
the  rate  via  a  Na+-Cl--K+  cotransport  mechanism  [66].  In
addition, PKCγ has a direct or indirect inhibitory effect on gap
junction communication in lens epithelial cells [67,68] via
phosphorylation  of  Connexin43  on  serine  and  this  causes
disassembly and loss of gap junction from the cell surface
[69].  PKC  also  plays  a  role  in  cataractogenesis  by
phosphorylating  proteins  from  calf  lens  fiber  membranes
[70] and activating neutral proteases [71]. The PKC-inhibiting
effect of vitamin E is known to exist in epithelial cells [72].
Intramuscular  vitamin  E  supplementation  is  sufficient  in
protecting  histopathologic  changes  in  the  lens  epithelium
[73].
Intracellular functions of vitamin E -beyond its general
antioxidant role was an interesting issue even in 1946 [20].
Today, molecular biology is an important discipline to solve
curent challenges in ophthalmology. It is already known that
certain isomers of vitamin E exert specific effects, and this
suggests that proper use of a correctly selected type of vitamin
E  is  likely  to  provide  a  significant  improvement  in  the
prevention  and  treatment  of  many  ocular  pathologies.
Numerous drugs with the potential to manipulate intracellular
signal transmission pathways are still being tried. However,
both  the  variations  between  the  receptor  and  ion-chanel
subtypes and the fact that a certain blocker binds to various
regions  in  a  condition-dependent  manner  preclude  the
production  of  therapeutics  that  will  bind  correctly  to  the
appropriate location. Also, side effects of those substances
gravely limit their clinical use. Currently, it is evident that
regarding correct and safe intracellular signal modulation, α-
tocopherol, a natural, safe, and cost effective drug, merits a
careful look beyond its mere antioxidant properties.
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